OGA抑制剂的突触毒性和Ceperognastat的失败
Jonathan Meade1, Haylee Mesa1, Lei Liu2
1The Stiles-Nicholson Brain Institute and Department of Chemistry and Biochemistry in College of Science, Florida Atlantic University, Boca Raton, FL, USA.
O-GlcNAcase抑制剂 (OGAi) 对阿尔茨海默氏症有望,但可能会导致突触损伤. 这项研究揭示了OGAi迅速损害突触可塑性并改变蛋白质水平,这表明它具有全类突触毒性作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- O-GlcNAcase抑制剂 (OGAi) 通过向tau病理来研究阿尔茨海默病 (AD).
- 最近的临床试验失败引发了OGAi疗法的安全问题.
研究的目的:
- 为了研究三种不同的OGAi的急性突触作用:ceperognastat,ASN90和MK8719.
- 为了确定OGAi是否表现出全类突触毒性.
主要方法:
- 在小鼠海马片中进行电生理学记录以评估突触可塑性.
- 免疫组织化学分析突触蛋白水平和陶酸化.
主要成果:
- 所有测试的OGAi都导致了短期和长期突触可塑性受损,包括配对脉冲促进/抑郁和长期强化.
- 突触蛋白质的改变包括增加PSD-95和减少Synaptophysin 1.
- 观察到陶酸化的双相转变.
结论:
- OGAi诱导快速,融合,并可能具有全类范围的协同毒性作用.
- 电生理学查对于中枢神经系统药物开发至关重要.
- 针对慢性神经退行性疾病的重要突触过程需要谨慎.
更多相关视频
08:16Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
Published on: September 21, 2021
15:05Functional Evaluation of Biological Neurotoxins in Networked Cultures of Stem Cell-derived Central Nervous System Neurons
Published on: February 5, 2015
相关概念视频
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Drugs Affecting Neurotransmitter Release or Uptake
